Investorideas.com newswire, defense and security sector

Monday, April 22, 2013

www.investorideas.com defense stocks blog- Homeland Security news

www.investorideas.com defense stocks blog- Homeland Security news
Two men arrested and charged Monday were part of an al Qaeda-supported plot to derail a passenger train, the Royal Canadian Mounted Police said.


The suspects, Chiheb Esseghaier and Raed Jaser, are accused of conspiring to kill people on a VIA train, police said. Officials said that the suspects had the capacity to carry out an attack but that the public was never in imminent danger.

The two men were receiving support "in the form of direction and guidance" from al Qaeda elements in Iran, police said. They are not Canadian citizens.
Follow complete coverage of breaking news on CNN TV, http://cnn.com and CNN Mobile.

Published at (www.investorideas.com defense stocks blog ) Research defense and Homeland Security stocks with the largest global defense stocks directory online for investors at Investorideas.com and www.Homelanddefensestocks.com click here: http://www.investorideas.com/Companies/HomelandDefense/Stock_List.asp Defense and security companies - Become a showcase defense stock at www.investorideas.com and www.homelanddefensestocks.com for as little as $1000 month

Thursday, April 18, 2013

Medical Technology Breaking News: Aethlon Medical (OTCBB:AEMD) Discloses Cancer and Infectious Disease Therapy Presentation at ISEV 2013

SAN DIEGO - April 18, 2013 (Investorideas.com newswire) - Aethlon Medical, Inc. (OTCBB: AEMD), disclosed that a poster presentation entitled: "Extracorporeal Exosome Removal: A Therapeutic Strategy to Address an Evolutionary Survival Mechanism Shared by Cancer and Infectious Viral Pathogens," is being presented today at the International Society of Extracellular Vesicles (ISEV) 2013 conference being held in Boston, MA. Dr. Annette Marleau, Director of Tumor Immunology at Aethlon Medical will give the presentation. Information related to ISEV 2013 can be accessed online at: www.isevmeeting.org

The Aethlon presentation discusses the specificity of the Aethlon Hemopurifier® to address evolved glycopathogen targets that are instrumental in cancer and infectious disease progression. Significant points addressed in the presentation include emerging knowledge of exosome secretion, which is a notable feature of malignancy owing to the diverse roles of these particles in tumor-mediated immune suppression, angiogenesis, metastasis, and resistance to therapeutic agents. As cancer-secreted exosomes remain a critical target not addressed by drug therapies, the Company is expanding the potential utility of the Hemopurifier® to include cancer. In this role, the Hemopurifier® provides an adjuvant strategy to improve current and emerging cancer treatment outcomes without adding drug toxicity. To date, pre-clinical Hemopurifier® studies have validated the capture of exosomes underlying breast cancer, metastatic melanoma, ovarian cancer, lymphoma, and colorectal cancer.
The Aethlon Hemopurifier® consists of the lectin Galanthus nivalis agglutinin (GNA) immobilized in the outer-capillary space of a plasma membrane device that is compatible for use with standard CRRT and dialysis units. GNA-based capture is mediated by unique high mannose signatures abundant on the surface of cancer-secreted exosomes as well as glycoproteins that reside on the outer membrane of infectious viral pathogens.
In human studies of treatment naive HIV and Hepatitis-C (HCV) infected individuals, Hemopurifier® therapy demonstrated average viral load reductions of greater than 50% during single four-hour treatment applications. A three-treatment Hemopurifier® protocol combined with interferon-based standard-of-care resulted in undetectable HCV in as little as seven days in hard-to-treat genotype-1 patients. In this same clinical program, post-treatment elution studies documented the capture of up to 300 billion HCV copies by the Hemopurifier® during a single six-hour treatment. A human feasibility study to initiate HCV human studies in the United States is pending IDE approval by the U.S. Food and Drug Administration (FDA).
Based on human treatment experience and exosome capture validations, the Company has identified candidate research centers to conduct a Hemopurifier® therapy study in cancer patients.
About Aethlon Medical
Aethlon Medical creates innovative medical devices that address unmet medical needs in cancer, infectious disease, and other life-threatening conditions. Our Aethlon ADAPT™ System is a revenue-stage technology platform that provides the basis for a new class of devices the rapid, yet selective removal of disease promoting particles from the entire circulatory system. At present, The Aethlon ADAPT™ product pipeline includes the Aethlon Hemopurifier® to address infectious disease and cancer, and a medical device being developed under a 5-year contract with Defense Advanced Research Projects Agency (DARPA) to reduce the incidence of sepsis in combat-injured soldiers. For more information, please visit www.aethlonmedical.com.
About The Aethlon Hemopurifier®
The Aethlon Hemopurifier® is a first-in-class medical device that selectively targets the rapid clearance of infectious viral pathogens and immunosuppressive proteins from the entire circulatory system. In the treatment of Hepatitis C virus (HCV), human studies have demonstrated that Hemopurifier® therapy may improve immediate, rapid and sustained virologic response rates when administered in the first few days of standard-of-care drug therapy. In addition to accelerating viral load depletion, post-treatment analysis of the Hemopurifier® has documented the capture of up to 300 billion HCV copies of HCV during a single six-hour treatment. Access to Hemopurifier® therapy is available on a compassionate-use basis through the Medanta Medicity Institute (Medicity), a leading center for medical tourism in India. The Medicity is offering treatment access to infected individuals who previously failed or subsequently relapsed standard-of-care drug regimens. The Hemopurifier® is also being offered as a salvage therapy to infected individuals who suffer a viral breakthrough during standard-of-care therapy. U.S. studies of the Hemopurifier® are currently pending approval of an IDE submitted to FDA.
The Aethlon Hemopurifier® and Cancer
In addition to the opportunity to address a broad-spectrum of infectious viral pathogens, the Hemopurifier® has been discovered to capture tumor-derived exosomes underlying several forms of cancer. Tumor-derived exosomes have recently emerged to be a vital therapeutic target in cancer care. These microvesicular particles suppress the immune response in cancer patients through apoptosis of immune cells and their quantity in circulation correlates directly with disease progression. Beyond possessing immunosuppressive properties, tumor-derived exosomes facilitate tumor growth, metastasis, and the development of drug resistance. By addressing this unmet medical need, the Hemopurifier® is positioned as an adjunct to improve established cancer treatment regimens.
Certain statements herein may be forward-looking and involve risks and uncertainties. Such forward-looking statements involve assumptions, known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Aethlon Medical, Inc. to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such potential risks and uncertainties include, without limitation, that the company can successfully protect its intellectual property, that removal of exosomes from the human body will impact or lead to successful treatment of cancer, or that exosomes are the cause of tumor growth and progression, that the FDA will not approve the initiation of the Company's clinical programs or provide market clearance of the company's products, future human studies whether revenue or non-revenue generating of the Aethlon ADAPT™ system or the Aethlon Hemopurifier® as an adjunct therapy to improve patient responsiveness to established cancer or hepatitis C therapies or as a standalone cancer or hepatitis C therapy, the Company's ability to raise capital when needed, the Company's ability to complete the development of its planned products, the Company's ability to manufacture its products either internally or through outside companies and provide its services, the impact of government regulations, patent protection on the Company's proprietary technology, product liability exposure, uncertainty of market acceptance, competition, technological change, and other risk factors. In such instances, actual results could differ materially as a result of a variety of factors, including the risks associated with the effect of changing economic conditions and other risk factors detailed in the Company's Securities and Exchange Commission filings. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.
Contacts:
James A. Joyce
Chairman and CEO
858.459.7800 x301
jj@aethlonmedical.com
Jim Frakes
Chief Financial Officer
858.459.7800 x300
jfrakes@aethlonmedical.com
Marc Robins
877.276.2467
mr@aethlonmedical.com
Published at Investorideas.com Newswire
More info on AEMD at Investorideas.com Visit: http://www.investorideas.com/CO/AEMD/
Disclaimer: Investorideas.com is a third party publisher of news and research. Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising. If you have any questions regarding information in this press release please contact the company listed in the press release. Aethlon Medical, Inc. is currently an annual news release client at Investorideas.com and compensates Investorideas.com $2425 quarterly to publish and distribute news with Investorideas and its syndication partners
Investorideas.com Disclaimer: http://www.investorideas.com/About/Disclaimer.asp
Investorideas.com Disclosure: http://www.investorideas.com/About/News/Clientspecifics.asp
BC Residents and Investor Disclaimer: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894

Wednesday, April 17, 2013

Homeland Security Stock, Homeland Security Corporation (OTC Markets: HSCC) Reports Alliance with Sense Technologies to Integrate Identification and Access Control Into Multiple Security Applications

WRIGHTWOOD, CA - April 16, 2013 (Investorideas.com newswire) Homeland Security Corporation (PINKSHEETS: HSCC) reported earlier in March that the company has formed a joint venture with Sense Technologies for the development, sale and support of additional identification methods, including Biometrics and Access control solutions to HSCC's existing product line. Sense Technologies is a custom developer and solution provider of integrated hardware and proprietary software targeting the Transportation, Pharmaceutical, Law Enforcement, Healthcare, Travel and Tourism, Time and Attendance and Access Control industries.

HSCC and Sense have formed an alliance to co-develop multiple security applications using HSCC surveillance and CCTV technologies with Biometric and access control solutions to positively identify all users accessing the system. The venture will add the most important layer of security which is to make sure an authorized individual is the one accessing the system or in some cases a machine. Combined with the products HSCC distributes and has developed, the result is a totally secure system with a complete "Audit" trail from start to finish. Sense website can be viewed at www.senseme.com.
The company plans to target existing and new clients and industries with newly developed systems. The Sense Frontend and Backend system has the ability to integrate with any biometric, including Iris, Face, Fingerprint, and Voice depending on the application required. The systems have been designed to positively identify an authorized user and grant access, allow entry or "dispense" a product based on the user's level of authorization or license.
"We are excited to partner with Sense to bring real life positive identification to our existing security solutions. This partnership will create a much needed 'Revenue Stream' and allow the company to enter and expand new markets with complete turnkey solutions," stated David Shade, CEO of Homeland Security Corporation.
About HSCC
Homeland Security Corporation - Security and Surveillance, Biometrics and Access Control Solutions, Legal, Regulatory compliance & Security Surveillance in Marijuana Markets
Homeland Security Corporation (OTC:HSCC.PK), is a leading innovator, consultant and implementer of advanced security driven technologies that can be deployed in any environment to meet a clients security or regulatory needs. The company has been in the security product and installation business since 2001. http://www.hscsurveillance.com/
Investor info and financials
http://www.homelandsecuritycorporation.com/investors/
Biometrics and Access Control Solutions
http://www.senseme.com/
SAFE HARBOR
Included in this release are certain "forward-looking" statements, involving risks and uncertainties, which are covered by the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, along with statements regarding Homeland's performance. Such statements are based on management's current expectations and are subject to certain factors, risks and uncertainties that may cause actual results, events and performance to differ materially from those anticipated.
Contact:
Homeland Security Corporation
David L. Shade
877-931-1999
Published at Investorideas.com Newswire
More info on HSCC at Investorideas.com Visit: http://www.investorideas.com/CO/HSCC/
Disclaimer/ Disclosure: The Investorideas.com is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising. All investment involves risk and loss of investment. Disclosure: HSCC has compensated investorideas.com the equivalent of $ten thousand per month in 144 shares for publishing news and content. Disclosure: http://www.investorideas.com/About/News/Clientspecifics.asp HSCC is not a fully reporting company. More info can be viewed at otcmarkets.com and the company websites.
BC Residents and Investor Disclaimer: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894

Biodefense Stock Alert; Aethlon Medical (OTCBB: AEMD) Moves Following News on Contract

Point Roberts, WA - April 17, 2013 (Investorideas.com newswire) - Investorideas.com, an investor research portal specializing in sector research for independent investors including biodefense and homeland security stocks issues a trading alert for Aethlon Medical, Inc. (OTCBB: AEMD), trading at $0.1099, up 0.0070 6.80% 12:43PM EDT on over 688,000 shares. The stock had a morning high of $0.12.

The company reported yesterday it entered into a subcontract agreement with Battelle Memorial Institute (Battelle) to provide services underlying a $22.8 million prime contract that was recently awarded to Battelle by the Defense Advanced Research Projects Agency (DARPA).
According to the press release, "The objective of this contract program is to integrate component technologies developed in DARPA's Dialysis Like Therapeutics (DLT) program into medical device that would save military and civilian lives by effectively treating sepsis. Beyond expanding our opportunity in the DLT program, we are honored to have the opportunity to work with Battelle (the world's largest independent research and development organization) on this endeavor."
The Company's Chairman and CEO also went on to say, "I am pleased to report that the funding spigot for countermeasures against bioterror and pandemic threats has been turned back on. Last month, The Pandemic and All-Hazards Preparedness Reauthorization Act (PAHPRA) of 2013 was signed into law by President Obama. The law reauthorizes provisions of the Project Bioshield Act of 2004 and extends the mandate of the Biomedical Advanced Research and Development Authority (BARDA) to support medical countermeasure development for biothreat agents for possible inclusion in the U.S. Strategic National Stockpile. PAHPRA also enhances the authority of the FDA to support rapid responses to public health emergencies by clarifying that even before an event occurs, FDA may issue an emergency use authorization to allow emergency use of certain products as medical countermeasures. The Congressional Budget Office estimates that $11 billion will be spent on PAHPRA between fiscal years 2014 to 2018."
Full news: http://finance.yahoo.com/news/aethlon-medical-aemd-note-government-133000119.html
Investorideas.com Newswire More info on AEMD: http://www.investorideas.com/CO/AEMD/
About Aethlon Medical
Aethlon Medical creates innovative medical devices that address unmet medical needs in cancer, infectious disease, and other life-threatening conditions. Our Aethlon ADAPT™ System is a revenue-stage technology platform that provides the basis for a new class of devices the rapid, yet selective removal of disease promoting particles from the entire circulatory system. At present, The Aethlon ADAPT™ product pipeline includes the Aethlon Hemopurifier® to address infectious disease and cancer, and a medical device being developed under a 5-year contract with Defense Advanced Research Projects Agency (DARPA) to reduce the incidence of sepsis in combat-injured soldiers. For more information, please visit www.aethlonmedical.com.
About InvestorIdeas.com:
InvestorIdeas.com is a leader in investor stock research by sector, featuring stock news, commentary and trading alerts in leading sectors including biotech, tech, mining, energy, water, renewable energy, beverage stocks and more.
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas
Follow Investorideas.com News on Linkedin.com/today at http://www.linkedin.com/today/investorideas.com
Sign up for the free news and stock alerts including biotech and biodefense stocks http://www.investorideas.com/Resources/Newsletter.asp
Become an Investorideas.com Member and access our 14 online stock directories 24/7 - biotech and life sciences, biodefense and homeland security , water, renewable energy, mining stocks http://www.investorideas.com/membership/
Disclaimer/ Disclosure : The Investorideas.com is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising. Disclosure: AEMD is a paid client for news release and content distribution on the investorideas.com newswire and syndication partners (annual fee program 9700)
http://www.investorideas.com/About/Disclaimer.asp
BC Residents and Investor Disclaimer: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894
800-665-0411 - Source - www.Investorideas.com

Monday, April 1, 2013

Homeland Security –Defense site for sale



Homeland Security –Defense site for sale




Investorideas.com has  the following website for sale

National Homeland Security Knowledgebase.com

call 800 665 0411

or Dvanzant@investorideas..com

About InvestorIdeas.com: Investor Ideas for global investors; invest in what you like!


www.InvestorIdeas.com is a meeting place for investors and public companies in leading sectors. Find investing ideas in biotech stocks, tech and mobile stocks, mining stocks, oil and gas, water stocks, renewable energy, beverage stocks, defense stocks, nanotech and more on TSX, OTC, NASDAQ and global exchanges.



The Investor Ideas newswire is a news source on Google news, Google Currents and Linkedin.com/Today news. Investorideas.com newswire is now available as a free mobile app for iPhone orAndroid. Go here or here for link



Follow Investorideas.com on Twitter

Follow Investorideas.com on Facebook

Follow Investorideas.com News on Linkedin.com/today
Sign up for free stock alerts at Investorideas.com

Become an Investorideas.com Member and access our online stock directories listing thousands of publicly traded stocks in over 14 leading sectors
Disclaimer/ Disclosure : The Investorideas.com is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. http://www.investorideas.com/About/Disclaimer.asp

This site is currently compensated by featured companies, news submissions and online advertising.

BC Residents and Investor Disclaimer : Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894

800-665-0411 - Source – www.Investorideas.com


Investorideas.com newswire